At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 220 enrolled
Drug / intervention
Betaferon/Betaseron +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The AVANTAGE Study - A Randomized, Multicenter, Phase IV, Open-label Prospective Study Comparing Injection Site Reaction and Injection Site Pain in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) or After a First Demyelinating Event Suggestive of MS Newly Started on Interferon Beta-1b (Betaferon®) or Interferon Beta-1a (Rebif®).
In Brief
A Phase 4 clinical trial evaluating Betaferon/Betaseron and Rebif for Relapsing-remitting Multiple Sclerosis. Completed, enrolled 220 participants across 59 sites.
Detailed Summary
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing-remitting Multiple Sclerosis
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedApr 2006
Primary CompletionApr 2008
TodayJul 2026
First PostedApr 25, 2006
Enrollment StartMar 1, 2006
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.2 years ago
Interventions
Betaferon/Betaserondrug
250ug administrated with Betaject
Rebifdrug
44ug administered with Rebiject II
Betaferon/Betaserondrug
250ug administrated with Betaject light